EP0608831A1 — Compositions containing argatroban analogs
Assigned to Mitsubishi Chemical Corp · Expires 1994-08-03 · 32y expired
What this patent protects
An antithrombin composition in the form of emulsion which comprises, together with a slovent, a diluent, and an emulsifier, N²-arylsulfonyl-L-arginineamide represented by the general formula (I): wherein R¹ represents (2R,4R)-4-alkyl-2-carboxypiperidino group, R² represe…
USPTO Abstract
An antithrombin composition in the form of emulsion which comprises, together with a slovent, a diluent, and an emulsifier, N²-arylsulfonyl-L-arginineamide represented by the general formula (I): wherein R¹ represents (2R,4R)-4-alkyl-2-carboxypiperidino group, R² represents phenyl group or a condensed polycyclic compound residue as defined below, and said R² optionally has one or more substituents selected from lower alkyl group, lower alkoxy group or amino group substituted by lower alkyl group, said condensed polycyclic compound residue being a condensed polycyclic compound residue including a benzene ring, said benzene ring being bound to the sulfur atom of the sulfonyl group in the general formula (I) and said benzene ring being condensed with other ring which may be a heterocyclic ring, and said polycyclic compound residue having 7 - 14 carbon atoms in total, its hydrate and/or its salt, is provided.
Drugs covered by this patent
- Argatroban (ARGATROBAN) · Hikma Pharm Co Ltd
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.